Lion TCR

Executive Summary

Lion TCR is a Singapore-based clinical-stage biotechnology company pioneering mRNA-encoded, virus-specific TCR-T cell therapies for HBV-related hepatocellular carcinoma (HCC) and other viral-associated cancers. The company's platform leverages a patented HBV-specific TCR library covering approximately 80% of Asian HLA types, enabling autologous TCR-T products with transient mRNA expression to enhance safety. Founded in 2020 and having raised $40 million, Lion TCR has advanced its lead product candidate into Phase 1 clinical trials. The company's approach addresses a significant unmet need in HBV-related HCC, a prevalent cancer in Asia with limited treatment options, and its technology holds promise for broader viral-oncology applications.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 Interim Safety and Efficacy Data Readout70% success
• Q2 2027IND Submission for Second Indication (e.g., EBV-associated cancers)60% success
• Q1 2027Strategic Partnership or Licensing Deal for Asian Markets50% success